Document:

Exhibit 10.21

 

CONFIDENTIAL

 

AMENDMENT No. 1

 

To

 

PHARMACEUTICAL
PRODUCT CO-DEVELOPMENT AND LICENSE AGREEMENT

 

THIS
AMENDMENT No. 1 TO THE PHARMACEUTICAL PRODUCT CO-DEVELOPMENT AND LICENSE AGREEMENT
(this “Amendment”), effective as of March ___, 2014 (the “Amendment No. 1 Effective
Date”), is made by and between Cancer Prevention Pharmaceuticals, Inc., (“CPP”) and Tillotts
Pharma AG, (“TILLOTTS”).

 

BACKGROUND

 

A.           CPP
and TILLOTTS entered into that certain Pharmceutical Product Co-Development and License Agreement effective December 27, 2013
(the “Agreement”);

 

B.           CPP
and TILLOTTS wish to modify the Agreement as set forth in this Amendment.

 

NOW
THEREFORE, for and in consideration of the covenants, conditions, and undertakings hereinafter set forth, it is agreed by and
between the parties as follows:

 

1.          All
defined terms have the meaning assigned to them in the Agreement unless otherwise expressly set forth in this Amendment.

 

2.          Clause
(c) of Section 4.3.1 is hereby deleted and replaced with the following:

 

(c) except
for those actions and decisions mandated by SECTION 4.3.2, TILLOTTS will have the final decision-making right and authority on
all matters directed to obtaining in the Licensed Territory MA Approval of the Licensed Formulation in the Licensed Field on or
after the date on which TILLOTTS makes or is deemed to make the Continued Development Election and pays the Continued Development
Election Fee.

 

This
Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument.

 

IN
WITNESS WHEREOF, the parties have caused their duly authorized representatives to execute this Amendment No. 1.

 

	Cancer
    Prevention	 	Tillotts
    Pharma AG
	Pharmaceuticals,
    Inc.	 	 
	 	 	 
	By:	/s/
    Jeffrey Jacob	 	By: 	/s/
    Dirk Reckert   /s/ Yves Kesch
	 	 	 
	Name: 	Jeffrey Jacob	 	Name:	Dirk Reckert/Yves Kesch
	 	 	 
	Title:	CEO	 	Title:	Chief Business Development Officer/General Counsel
	 	 	 
	Date:	3-31-14	 	Date:	March 24, 2014Exhibit 10.22

 

AGREEMENT

S0820 – CANCER PREVENTION PHARMACEUTICALS,
INC.

 

This Agreement is hereby entered into by
and between the SWOG (the “Group”), in conjunction with the SWOG Clinical Trials Initiative, LLC (“CTI”)
located at 24 Frank Lloyd Wright Drive, Ann Arbor, Michigan 48106 and Cancer Prevention Pharmaceuticals, Inc. (the “Company”),
having a business at 1760 E. River Road – Ste. 250, Tucson, AZ 85718 agree as set forth below. The Effective Date of this
Agreement is the date of final signature.

 

RECITALS

 

The research study or protocol contemplated
by this Agreement is of mutual interest and benefit to the Group and to the Company, and will further the instructional and research
objectives of Group in the manner consistent with its Charter and Bylaws.

 

Now, therefore, in consideration of the
promises and mutual covenants herein contained, the parties agree as follows:

 

		1.0	Performance of Protocol. Subject to the Company’s compliance with the terms and conditions
hereof, the Group shall use its reasonable best efforts to perform the study in accordance with the protocol S0820, “A Double
Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Rick Adenomas and Second Primary Colorectal
Cancers in Patients with Stage 0-III Colon Cancer, Phase III”, attached hereto as Attachment A, (the “Study”)
substantially in accordance with the terms thereof.

 

		1.1	In the event the Group becomes unable to complete the Study or protocol, including based on discontinuation,
reduction or denial of funding from the NCI, the Group shall have the option to terminate the study or protocol upon reasonable
prior written notice to the Company. Either party may terminate the Study upon reasonable prior written notice to the other in
the event either party believes in good faith that the safety of subjects is jeopardized, the authorization and approval to perform
the Study or protocol is withdrawn by the United States Food and Drug Administration (the “FDA”), or other regulatory
agency, or for breach of any of the terms and conditions of this Agreement where such breach is not remedied within thirty (30)
days after receipt of written notice thereof from the other party.

 

		1.2	If the Study is terminated, for any reason other than breach by the Group, the Company shall reimburse
the Group for non-cancelable expenses and costs actually incurred by the Group as set forth in the budget through the effective
date of termination, such reimbursement not to exceed the total Study cost listed in the budget. Any termination, other than termination
due to Group’s breach of this Agreement, shall not entitle the Company to any refund of amounts paid or due to the Group.

 

		1.3	The Group will and will ensure that all investigators performing the Study, comply with all applicable
laws and regulations.

 

		2.0	Costs, Billings, and Other Support.

 

		2.1	The Company will provide Study Drug, DFMO (eflornithine), at no cost, for all registered patients
accrued to this Study as set forth in the protocol, Attachment A. In support of the Study, Company will provide CTI, who
receives funds on behalf of the Group, with a total amount to support study and administrative costs in accordance with the budget,
attached as Attachment B. All payments due hereunder shall be paid by Company within forty-five (45) days from its receipt
of an undisputed invoice for such payment. Payment shall be made by Company to Group at the address set forth above. CTI’s
tax identification number is 26-1146046.

 

     

     

    

 

		2.2	Should the Company request statistical analyses, data management case report forms, or non-standard
Group forms, which are not included in the budget and are over and above the standard statistical or data management measures normally
carried out in the conduct of a major clinical trial, additional funding negotiations and modification of this Agreement will be
required.

 

		2.3	The Company shall provide the Group with all materials and items (particularly information that
may impact on patient safety) which, pursuant to the Study (Attachment A) must be provided by the Company in order to enable the
Group to perform the Study.

 

		2.4	The Group shall notify the company of Serious Adverse Events (“SAE”) that occur in
the course of the Study in accordance with the applicable government requirements and the Protocol. As soon as the Group receives
notification of a SAE, but no later than one working day, the notification will be reported using the AdEER’s system to kgrenier@canprevent.com,
acohen@canprevent.com, and cbrannen@canprevent.com. It is the Company’s responsibility to ensure that the Group
has the most current contact information for reporting SAEs, as defined by the criteria listed in Section 16 of the Protocol, to
the Group immediately, but no later than twenty-four (24) hours after the event occurs.

 

		3.0	Compliance with Applicable Regulations. The Group understands its obligations to comply
with applicable provisions of the Federal Food, Drug and Cosmetics Act, 21 U.S.C. § 301 et seq., and regulations promulgated
thereunder, including, if applicable, the provisions of 45 CFR 46, “Protection of Human Subjects” (in particular Sections
46.116 and 46.117). The Group understands that it is its responsibility to obtain any necessary or appropriate clearances for the
services it performs. The Group also understands that it is subject to requirements to maintain procedures to assure continued
monitoring and compliance with those requirements during the performance of the Study.

 

		4.0	Data Collection. The Group will,
through its Statistical Center co-located at the Fred Hutchinson Cancer Research Center and at Cancer Research and Biostatistics,
both in Seattle, Washington, register patients involved in the Study or protocol, maintain a database pertinent for the Study,
and conduct the interim and final analyses in accordance to the terms of the Study. The Company understands, however, that the
Group abides by the policy of the Data and Safety Monitoring Committee to avoid the dissemination of interim analyses which may
be premature, inconclusive, or misleading. No data analyses showing treatment arm contrasts will be made public or provided to
the Company unless the Data and Safety Monitoring Committee so decides. Reports generated from the data base pertinent to the Study
will be made available to the Company when the Data and Safety Monitoring Committee approves such release, or at the time the study
results are submitted for publication, whichever is earlier.  The
Group’s policy does not permit anyone with a financial conflict of interest to participate in the Data and Safety Monitoring
Committee deliberations; Company representation is thus excluded. 

 

		5.0	Statement of Principles Regarding FDA Testimony

 

			The parties acknowledge that the Company may use data from the Study to support a new drug application
(“NDA”) to the Food and Drug Administration (FDA). It is recognized that certain individuals, such as the trial’s
study coordinator and/or statistician, may be requested by the Company to appear before the FDA or its advisory committees to present
the data generated by the trial. While the provision of standard data and reports to Company is included as part of this Agreement,
this Agreement does not obligate any member of the Group to present such data before the FDA or its advisory committees
in support of an NDA. Any such appearance shall be at the discretion of the investigator and should be accompanied by appropriate
disclosure regarding financial compensation received by the individual from the Company. Notwithstanding the foregoing, the Group
agrees to use commercially reasonable efforts to cooperate with the Company in connection with any communications with the FDA.

 

    	 	2	 

     

    

 

		5.1	Documentation. (FDA Form 1572, CV, and Financial Disclosure Form). If requested by the FDA,
the Pharmaceutical Management Branch (“PMB”) will provide a copy of the FDA Form 1572 and CV for the principal investigator
and any co-investigator listed on the title page of the protocol on file with Cancer Therapy Evaluation Program (“CTEP”)
Protocol and Information Office. Please note that the PMB is not able to provide copies of the FDA Form 1572 and CVs for all participating
investigators unless specifically requested to do so in writing by the FDA. In such a case, reimbursement for staff time and copying
expenses to retrieve, copy and re-file the documents will require further negotiation and modification of this Agreement.

 

		5.2	The Group does not maintain financial disclosures, 1572s or IRB approvals. The Group uses a central
file kept and maintained by the National Cancer Institute (“NCI”) and the Cancer Trials Support Unit (“CTSU”).
The Group’s database uses a date field with data provided by the NCI to ensure that the information is on file and current
before registration to any study may occur. The 1572s and IRB approvals are available for request by the FDA only and would be
provided directly from the NCI to the FDA. The NCI will not provide financial disclosures to the Company. Should the Company require
financial disclosures for an NDA, arrangements will be made with the Group to collect Study specific financial disclosures from
registering investigators after the Study has been completed. Financial support for the collection of financial disclosures will
require further negotiation and modification of this Agreement.

 

		6.0	Information; Publications.

 

		6.1	Company recognizes the necessity for preserving the spirit of free and open inquiry among clinical
investigators. Data generated in sponsored and non-sponsored studies are the property of the Group; however, data from the Study
shall be made available to the Company for FDA submission. Data will be transferred as follows: (1) Prior to publication, data
pertaining to registration (without treatment assignment), eligibility, and adverse events, will be provided in conjunction with
the semi-annual Report of Studies Summary or on request; (2) After DSMC release of data, SWOG Statistical Center will work with
Company to provide the same data set for Company’s regulatory use that SWOG will use for publication so that the two processes
can go forward in parallel, reporting final results for the primary endpoint, data pertaining to registration, eligibility, adverse
events, and treatment outcomes (the “3-year event rate” – defined per protocol as high risk andenoma or 2nd
primary colorectal cancer – along with cancer recurrence and mortality). If necessary and requested by Company, a test data
set for Company to use in developing programs for its analysis will be provided. Transfers will require thirty (30) days notice
to process and complete. Should Company request statistical data or support in addition to what has been defined above, subsequent
funding negotiations and modification of this Agreement will be required. The data from other sponsored and non-sponsored studies
may be made available to Company provided the release of such data would not breach other contractual obligations of the Group,
the Group receives a written request for such data, and the Group is otherwise able to accommodate the request. The Company understands
that case report forms, if provided, will be supplied with patient identifiers redacted. Company further understands that all patient-identifiable
information must be and will remain confidential.

 

		6.2	The Company recognizes that under Group policy, the results of the Study undertaken by the Group
must be published and agrees that researchers engaged in the Study in the Group reserve the right to present and publish the data
at symposia, national or regional professional meetings, in professional journals, or through other means of their own choosing,
the data, methods and results of the Study undertaken under this Agreement. The Group recognizes that the Company intends to use
the Study Data for the purpose of obtaining or maintaining regulatory approval of DFMO and the Group accordingly agrees not to
intentionally allow any third party to use such Study Data for the purpose of regulatory filings with respect to DFMO. Further,
the Group agrees that it will not to sell or license, or consent to the sale or license of, Study Data to any third party or use
Study Data for any commercial or regulatory purposes, except as otherwise expressly provided in this Agreement or without the express
written consent of The Company.

 

    	 	3	 

     

    

 

		6.3	The Group undertakes to advise its researchers working on the Study that manuscripts shall be submitted
to the Company no less than thirty (30) days prior to submission of such manuscripts for publication, to allow the Company to review
for accuracy of background information and any patent opportunities. In the event the Company elects to take patent action, the
Group agrees to delay submission for an additional 60 days. However, it is understood and agreed that the Group does not maintain
a pre-clearance procedure for manuscripts prepared by its researchers, and the Group is not obligated to the Company to insure
that such manuscripts are so provided. In all events, the Group and its researchers shall have final authority to determine the
scope and content of any presentation or publication.

 

		6.4.	The Group in no way wishes to receive confidential information. The Company acknowledges the option
to enter into confidentially agreements with individuals outside of this Agreement. Such agreements would be at the discretion
of the individuals and in no way effect this Agreement.

 

		7.0	Intellectual Property Option to Collaborator:

 

The Group has advised Company
that all participating Group institutions, via their cooperative agreements, agreed to be bound, by the “NCI Notices of Grant
Award” and the Terms of Award Additions. These terms of award indicate the obligations that cooperative group institutions
have to the Company as the “Collaborator” in this Study.

 

It is understood by the Group
that one of the additional terms of award that the NCI has appended to the Notices of Grant Award defines the intellectual property
obligations that the cooperative group institutions participating in the Study have to the Company. These terms of award are posted
at http://ctep.info.nih.gov/industry/ipo.html and indicate the following:

 

Each Institution agrees to promptly
notify the NCI and “Collaborator” in writing of any inventions, discoveries or innovations made by the Institution’s
principal investigator or any other employees or agents of such Institution, whether patentable or not, which are conceived and/or
first actually reduced to practice in the performance of this Study using DFMO (hereinafter “Institution Inventions”).

 

Each Institution agrees to grant
to Collaborator: (i) a paid-up nonexclusive, nontransferable, royalty-free, world-wide license to all Institution Inventions for
research purposes only; and (ii) a time-limited first option to negotiate an exclusive, world-wide royalty-bearing license for
all commercial purposes, including the right to grant sub-licenses, to all Institution Inventions on terms to be negotiated in
good faith by Collaborator and such Institution. Collaborator shall notify such Institution, in writing, of its interest in obtaining
an exclusive license to any Institution Invention within six (6) months of Collaborator’s receipt of notice of such Institution
Invention(s). In the event that Collaborator fails to so notify such Institution, or elects not to obtain an exclusive license,
then Collaborator’s option shall expire with respect to that Institution Invention, and such Institution will be free to
dispose of its interests in such Institution Invention in accordance with such Institution’s policies. If such Institution
and Collaborator fail to reach agreement within ninety (90) days, (or such additional period as Collaborator and such Institution
may agree) on the terms for an exclusive license for a particular Institution Invention, then for a period of six (6) months thereafter
such Institution shall not offer to license the Institution Invention to any third party on materially better terms than those
last offered to Collaborator without first offering such terms to Collaborator, in which case Collaborator shall have a period
of thirty (30) days in which to accept or reject the offer.

 

    	 	4	 

     

    

 

Each Institution agrees that
notwithstanding anything herein to the contrary, any inventions, discoveries or innovations, whether patentable or not, which are
not Subject Inventions as defined in 35 USC 201(e), arising out of any unauthorized use of DFMO and/or any modifications to DFMO,
shall be the property of the Collaborator (hereinafter “Collaborator Inventions”). Each Institution will promptly notify
the Collaborator in writing of any such Collaborator Inventions and, at Collaborator’s request and expense, will cause to
be assigned to Collaborator all right, title and interest in and to any such Collaborator Inventions and provide Collaborator with
reasonable assistance to obtain patents (including causing the execution of any invention assignment or other documents). Each
Institution may also be conducting other more basic research using DFMO under the authority of a separate Material Transfer Agreement
(“MTA”), or other such agreement with the Collaborator. Inventions arising thereunder shall be subject to the terms
of the MTA, and not to this clause.

 

Protection of Proprietary Data:

“Clinical Data and Results
and Raw Data will be provided exclusively to the NCI, the Collaborator, and the FDA, as appropriate. This provision shall not affect
the investigators right to publish or present as described in the standard protocol language.”

 

This statement ensures that data
generated using an investigational agent proprietary to a Collaborator will be kept confidential and shared only with the NCI,
the FDA, and the Collaborator. Furthermore, this addresses the needs of the Collaborator to have access to the patient records
and raw data; it has no effect on the investigator’s right to publish.

 

35 USC(e):

“(e) The term “subject
invention” means any invention of the contractor conceived or first actually reduced to practice in the performance of work
under a funding agreement: Provided, that in the case of a variety of plant, the date of determination (as defined in section 41(d)
(FOOTNOTE 1) of the Plant Variety Protection Act (7 U.S.C. 2401(d))) must also occur during the period of contract performance.”

 

		8.0	Records. The Group shall maintain records for the Study until the later of: (a) two
(2) years following the date of approval of an NDA submitted by or on behalf of the Company; or (b) two (2) years after the
Company’s Investigational New Drug Application for DFMO is terminated or withdrawn.

 

		9.0	No Debarment. The Group represents and warrants that it shall not knowingly employ, contract
with, or retain any person directly or indirectly to perform the Study under this Agreement if such a person (a) is under investigation
by the FDA for debarment or is presently debarred by the FDA pursuant to 21 U.S.C. § 335a, or (b) has a disqualification hearing
pending or has been disqualified by the FDA pursuant to 21 CFR § 312.70 or its successor provisions. In addition, the Group
represents and warrants that it has not engaged in any conduct or activity which could lead to any of the above-mentioned disqualification
or debarment actions. If during the term of this Agreement the Group or any person employed or retained by it to perform the Study
(i) comes under investigation by the FDA for a debarment action or disqualification, (ii) is debarred or disqualified, or (iii)
engages in any conduct or activity that could lead to any of the above-mentioned disqualification or debarment actions, the Group
shall immediately notify the Company of same.

 

		10.0	Indemnification. No indemnification for any loss, claim, damage, or liability is intended
or provided by either party under this Agreement. Each party shall be liable for any loss, claim, damage, or liability that said
party incurs as a result of said party’s activities under this Agreement.

 

    	 	5	 

     

    

 

		11.0	Liability Disclaimer. It is understood that neither party shall be responsible for the acts
or omissions of the other party. Neither party shall be liable before or after termination of this agreement under any contract,
strict liability, negligence or other legal or equitable theory (a) for any direct, special, incidental, consequential or other
damages related to any product, material, equipment, service or other item provided hereunder by the company, or any product, material,
equipment, service or item supplied to third-parties by the company as a result of a protocol or study conducted hereunder or (b)
for cost of procurement of substitute services or any special, incidental or consequential damages related to any subject matter
of an obligation under this agreement. The group’s sole responsibility with respect to the study is to use its reasonable
best efforts in performing the study according to the terms of the protocol, this agreement and attachment a. The group understands
and agrees that DFMO supplied hereunder is experimental in nature and that no warranty, either express or implied, is made by the
company with respect thereto.

 

		12.0	Other Provisions.

 

		12.1	Neither party shall be held responsible for a delay or failure in performance under this Agreement
arising out of causes beyond its control or without its fault or negligence.

 

		12.2	This Agreement, Attachments A and B, and the Notices of Award referenced in Section 7.0 contain
the entire agreement of the parties on the subject matter to which this Agreement relates and supersede any price proposals, discussions,
and writings, by and between the parties, on such subject.

 

		12.3	No commitment or modification hereof shall be valid or binding upon the parties unless made in
writing and signed by authorized representatives of both parties. No waiver by either party of any breach of this Agreement shall
be deemed a waiver of any other than existing or subsequent breach, nor shall any such waiver by any party be deemed to be a continuing
waiver. No delay or omission by any party in exercising any right hereunder, at law or in equity, or any otherwise, shall impair
any such right, or be construed as a waiver thereof, or any acquiescence therein, nor shall any single or partial exercise of any
right preclude other or further exercise thereof, or the exercise of any other right.

 

		12.4	Any payment, notice or other communication required or permitted to be given under shall be deemed
to have been properly given and effective on the date of delivery if delivered in person or when mailed by first-class certified
mail, postage pre-paid, to the respective address given below, or to such other address as shall be designated by written notice
to the other party as follows:

 

	In the case of the Company:	Jeffrey Jacob, CEO
	 	Cancer Prevention Pharmaceuticals, Inc.
	 	1760 E. River Road – Ste. 250
	 	Tucson, AZ 85718
	 	 
	In the case of the Group:	SWOG
	 	Laurence H. Baker, D.O., Chairman
	 	24 Frank Lloyd Wright Drive  -  P.O. Box 483
	 	Ann Arbor, MI 48106

 

		12.5	The Company acknowledges that a conflict of interest does exist with a Principal of The Company
and the Group, and that the Group has instituted a management plan for handling that conflict.

 

    	 	6	 

     

    

 

		12.6	This Agreement shall become effective on the Effective Date and shall continue until the delivery
of the final report of the results of the Study or protocol unless sooner terminated in accordance with the provisions of this
Agreement. The parties hereto may, however, extend the term of this Agreement for additional periods as desired upon mutually agreeable
terms and conditions, which the parties reduce to writing and sign.

 

		12.7	In the event that either party hereto shall commit any breach of or default in any of the terms
and conditions of this Agreement, and shall also fail to remedy such default or breach within thirty (30) days after receipt of
written notice thereof from the other party hereto, the party giving notice may, after such thirty (30) day period, at its option
and in addition to any other remedies which it may have at law or in equity, terminate this Agreement by sending notice of termination
in writing to the other party to such effect, and such termination shall be effective as of the date of receipt of such notice.

 

		12.8	The relationship between the parties is that of independent contractors, neither party is authorized
nor shall represent itself as being authorized to act as agent for, or enter into agreements which are binding on the other party,
except to the extent approved in writing in advance by the Company. Group shall not make any commitments to investigators on behalf
of the Company. If any provision of this Agreement should be held invalid or unenforceable, the remaining provisions shall be unaffected
and shall remain in full force and effect, to the extent consistent with the intent of the parties as evidenced by this Agreement
as a whole.

 

The parties have caused this Agreement
to be executed by their duly authorized representatives as follows:

 

	CANCER PREVENTION	 	 
	PHARMACEUTICALS, INC.	 	SWOG
	(Company)	 	(Group)
	 	 	 	 	 
	BY:	/s/ Jeffrey Jacob	 	BY:	/s/ Laurence Baker
	 	Jeffrey Jacob	 	 	Laurence H. Baker, D.O.
	Its:	Chief Executive Officer	 	Its:	Chairman
	 	 	 
	Date: 	2/18/11	 	Date: 	2/22/11
	 	 	 	 
	 	 	 	SWOG - CLINICALTRIALS INITIATIVE (CTI)
	 	 	 	 	 
	 	 	 	BY:	/s/ Johanna Horn
	 	 	 	 	Johanna Horn, MSW
	 	 	 	Its:	Executive Director, The Hope Foundation for SWOG-CTI
	 	 	 	 	 
	 	 	 	Date: 	2/22/11

 

    	 	7	 

     

    

 

ATTACHMENT “A”

 

THE PROTOCOL

Pg.1

 

    	 	8	 

     

    

 

Attachment “B”

1-28-11

BUDGET AND PAYMENT SCHEDULE

 

for

 

SWOG Study #S0820 entitled, “A
Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary
Colorectal Cancers in Patients with Stage 0-III Colon Cancer, Phase III

 

SCOPE OF WORK:

 

		1.	Company will provide a sufficient supply of study drug, DFMO, (Eflornithine), at no cost, for all
patients registered to this Study directly to the NCI for distribution;

 

		2.	Company will provide funds to SWOG-CTI in the amount of $112,500.00 to cover the costs associated
with PK Analysis. The total number of PK patients is estimated to be 180 of the 1340 expected registrations. (180 pts. * $500 per
patient) = $90,000.00.

 

		3.	Company will provide funds to SWOG-CTI to cover the costs for Cancer Research and Biostatics (CRAB)
who will provide Company with data for this Study. The cost for two (2) data requests is $20,000.00. Should additional data requests
be required, the cost is $10,000 per request.

 

		4.	Facilities and administrative costs associated with conduction this trial are $27,500.00, which
is equal to 25% of the costs outlined above.

 

		5.	If electronic Case Report Forms are requested by Company, the cost is $80.00 per form. This budget
does not include the cost for any eCFR’s.

 

BUDGET:

 

	PK Collection	 	$	90,000.00	 
	 	 	 	 	 
	(2) Data Transfer Requests	 	 	20,000.00	 
	 	 	 	 	 
	Facilities & Administrative Costs	 	 	27,500.00	 
	 	 	 	 	 
	Total Budget:	 	$  	137,500.00	 

 

PAYMENT SCHEDULE:

 

	Payment 1	 	$	13,750.00	 	 	Due within thirty (30) days of contract signing:  50% of Administrative Costs
	Payment 2	 	 	22,500.00	 	 	Upon enrollment of first PK patient
	Payment 3	 	 	22,500.00	 	 	When 25% of PK patients have entered the Study
	Payment 4	 	 	22,500.00	 	 	When 50% of PK patients have entered the Study
	Payment 5	 	 	22,500.00	 	 	When 100% of patients’ PK samples have been received by CPP 
(or designated contractor)
	Payment 6	 	 	13,750.00	 	 	When 100% of patients entered the Study:  50% of Administration Costs
	Payment 7	 	 	20,000.00	 	 	(2) Data transfers – as requested during course of the Study
	TOTAL:	 	$	137,500.00	 	 	 

 

    	 	9

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00252-of-00352.parquet"}]]